Bicara Therapeutics Executives Stick to the Plan: CMO Raben David Buys 5,500 Shares at $3.79 After Selling at $18.95, Reinforcing Long‑Term Confidence in the Pipeline

Insider Trading Pulse at Bicara Therapeutics

Routine Buying Amid a Quiet Market On March 25, 2026, Chief Medical Officer Raben David executed a Rule 10b‑5‑1‑plan purchase of 5,500 shares at $3.79, boosting his stake to 60,786 shares. This move follows a recent sell of 5,500 shares at $18.95 on the same day, and a sale of 5,500 option‑shares at $0.00, indicating a structured trading window rather than a signal of confidence or concern. The average market price was $18.92, so the buy was made at roughly 20 % below the prevailing level, a pattern that has appeared consistently in David’s recent transactions (e.g., 16,300 shares bought at $3.79 in early March).

What This Means for Investors David’s purchases are typical of a “regular‑plan” strategy that insiders use to accumulate shares over time without influencing the market. The timing—late in the trading window, after a sell—suggests a disciplined approach rather than opportunistic buying on a breakout. For investors, this reinforces the notion that Bicara’s insider activity is routine and not a harbinger of impending earnings surprises or strategic shifts. The company’s stock has been on an uptrend (41 % YTD) but remains volatile, and the insider buying is unlikely to drive significant price movement.

David’s Transaction Profile Across the past year, David has alternated between buying and selling at the same price points: $3.79 for purchases and $18‑19 for sales. His option sales (e.g., 19,789 shares sold in December 2025) often coincide with the exercise of a large block of options, a pattern that indicates he is monetizing vested options while maintaining a substantial holding (over 55,000 shares). His net position has grown modestly, reflecting a long‑term investment thesis rather than short‑term speculation. Unlike some executives who use option sales to fund personal needs, David’s pattern aligns with a “buy‑and‑hold” strategy typical of clinical‑stage biotechs where management believes in the long‑term value of the pipeline.

Broader Insider Landscape Other key figures—Chief Financial Officer Hyep Ivan and President & COO Ryan Cohlhepp—have engaged in similar 10b‑5‑1‑plan trades, buying and selling at comparable price ranges. The company’s insiders collectively hold a sizeable block, but their activity remains within the bounds of routine trading. No large block trades or concentrated sell‑off signals suggest a looming liquidity event or management exit.

Bottom Line for the Market Bicara’s insider trading activity today underscores a disciplined, long‑term approach by its top executives. The buying at a discount to the market price, paired with consistent option sales, points to a strategy of gradual accumulation rather than reaction to short‑term news. For investors, the data supports a view that management remains confident in the company’s therapeutic pipeline and is positioning itself for future upside, while the stock’s recent gains continue to be driven by broader market sentiment and the biotech sector’s positive trajectory.